on behalf of the STABILITY Investigators* Background--We evaluated lipoprotein-associated phospholipase A 2 (Lp-PLA 2 ) activity in patients with stable coronary heart disease before and during treatment with darapladib, a selective Lp-PLA 2 inhibitor, in relation to outcomes and the effects of darapladib in the STABILITY trial.
I nflammatory activity is an integral component of the development of atherosclerosis and its complications. 1 Biomarkers indicating myocardial dysfunction (eg, troponin, natriuretic peptides), renal dysfunction (eg, cystatin C), and inflammatory activity (eg, C-reactive protein) are risk indicators of future cardiovascular events in healthy persons and in patients with established coronary heart disease (CHD). [2] [3] [4] [5] Higher levels of lipoprotein-associated phospholipase A 2 (Lp-PLA 2 ) activity have also been associated with an increased risk of coronary events in healthy elderly persons and in patients with stable CHD. [6] [7] [8] [9] There is some evidence that Lp-PLA 2 might be part of the atherosclerotic process and may contribute to plaque destabilization through inflammatory activity in the atherosclerotic lesions. [10] [11] [12] Consequently, it is important to further evaluate the independent prognostic value of Lp-PLA 2 activity as a risk marker for individual nonfatal and fatal cardiovascular events in large long-term 19 The present predefined ancillary study evaluated the independent prognostic value of baseline Lp-PLA 2 activity concerning cardiovascular events, the reduction of Lp-PLA 2 activity by darapladib, and the associations between baseline and changes in Lp-PLA 2 activity and clinical outcomes.
Methods
Trial Design, Patients, Treatments, and Follow-up
The STABILITY trial was a prospective double-blind randomized trial evaluating the efficacy and safety of darapladib 160 mg, a specific inhibitor of Lp-PLA 2 , compared with placebo concerning cardiovascular outcomes in patients with stable CHD. 19 In brief, the study randomized 15 828 patients from 39 countries with stable CHD, defined as prior MI, prior coronary revascularization, or multivessel CHD confirmed by coronary angiography. Patients also had to meet at least 1 of the following cardiovascular risk criteria: age ≥60 years; diabetes mellitus requiring pharmacotherapy; high-density lipoprotein cholesterol <1.03 mmol/L; current or previous smoker, defined as ≥5 cigarettes per day on average; significant renal dysfunction (estimated glomerular filtration rate ≥30 and <60 mL/min per 1.73 m 2 or urine albumin:
creatinine ratio of ≥30 mg albumin per gram of creatinine); or polyvascular disease (CHD and cerebrovascular disease or CHD and peripheral arterial disease). The patients were followed with regular outpatient visits for a median of 3.7 years. The primary outcome was the composite of cardiovascular death, nonfatal MI, or nonfatal stroke. Secondary outcomes were the composites of major coronary events (ie, fatal and nonfatal MI, death from CHD, or urgent coronary revascularization for myocardial ischemia) and the composite of total coronary events, which also included all coronary revascularizations. Additional secondary end points were the individual components of the primary composite end point, hospitalization for heart failure, and all-cause mortality.
Components of cardiovascular death included death from unknown cause, fatal MI, fatal stroke, complications of a cardiac procedure, arrhythmia, congestive heart failure or shock, other vascular cause of death, and sudden death. All suspected end points were documented and reported by STABILITY study investigators and were adjudicated by an independent clinical events committee. All participants provided informed consent, and the study was approved by the relevant institutional review committee in each participating country.
Samples and Biochemical Methods
Blood samples were obtained from the majority of patients at baseline and 24AE2 hours after the last intake of study drug at months 1, 3, 6, and 18, and at the end of treatment. Plasma aliquots were stored in central repositories at À70°C until biochemical analysis was performed. Measurements of Lp-PLA 2 activity and other biomarkers were performed in 14 500 patients at baseline for whom samples were available and suitable for assay. For 13 709 of these patients, Lp-PLA 2 activity was also measured after 1 month. In addition, the change in Lp-PLA 2 activity over a longer time period was evaluated in a random sample of 100 patients with plasma samples available from all follow-up visits. The sample size of 100 patients was based on the assumption of a mean difference in percentage change from baseline between treatment groups in Lp-PLA 2 activity of between 25% and 65%, with a common standard deviation of 25%, a 2-sided type I error rate (a level) of 5% and power of 90%. In total, 100 participants were selected with the goal of having %50 participants from each treatment group to describe the long-term inhibition of Lp-PLA 2 activity by the randomized treatment.
The Lp-PLA 2 activity was measured in an automated enzyme assay system (PLAC Test for Lp-PLA 2 Activity; Diadexus) with a colorimetric substrate that is converted on hydrolysis by the phospholipase enzyme. The analytical sensitivity (limit of quantitation) of the assay is 10 lmol/ min per liter. Within-run and within-laboratory variability were determined by testing 4 human plasma samples and 2 controls with Lp-PLA 2 activities ranging from 113 to 315 lmol/min per liter. Samples were assayed in duplicate twice a day over 20 days and with 3 kit lots using 1 instrument. Total precision coefficients of variation for each reagent lot and sample were <3%. Several dilution series were prepared from plasma samples with known high and low Lp-PLA 2 activity levels and were tested with 3 kit lots. Linearity with a deviation of ≤10% was demonstrated from 10 to 382 lmol/min per liter, which is considered the measuring range of the assay. The Lp-PLA 2 activity measurements were performed by the manufacturer (Diadexus) on samples blinded for study treatment. The levels of high-sensitivity cardiac troponin T, N-terminal proB-type natriuretic peptide, growth differentiation factor 15 (precommercial assay), 20 and cystatin C were determined by electrochemiluminiscence immunoassays using a Cobas Analytics e601 system (Roche Diagnostics), performed at the Uppsala Clinical Research Center Laboratory at Uppsala University in Sweden. Highsensitivity C-reactive protein was analyzed using the CardioPhase high-sensitivity C-reactive protein (Dade Behring) 2-site particle-enhanced immunonephelometry sandwich assay. The routine biochemical analyses and high-sensitivity C-reactive protein assay were performed at a central laboratory with standardized methods (Quest Diagnostics Clinical Laboratories, Inc). (B) in women, and (C) in men, adjusted for demographics, baseline characteristics, routine biochemical variables, and prognostic biomarkers. The x-axis presents a logarithmic scale. MACE indicates CV death, MI, or stroke; MCE indicates coronary heart disease death, MI, or urgent coronary revascularization. Event rates are Kaplan-Meier rates. Adjustment variables: randomized treatment, geographic region, age, sex, body mass index, current smoking, hypertension, diabetes mellitus, prior MI, prior coronary revascularization, multivessel coronary heart disease, polyvascular disease, significant renal dysfunction, routine biochemical variables (hemoglobin, white blood cell count, estimated glomerular filtration rate [Chronic Kidney Disease Epidemiology Collaboration], low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and triglycerides), and prognostic biomarkers (Nterminal proB-type natriuretic peptide, high-sensitivity cardiac troponin T, cystatin C, high-sensitivity C-reactive protein, and interleukin 6). CV indicates cardiovascular; HR, hazard ratio; Lp-PLA 2 , lipoprotein-associated phospholipase A 2 ; MACE, major adverse cardiac events; MCE, major coronary events; MI, myocardial infarction; Q, quartile. Demographics and other baseline characteristics were summarized by quartile group of the baseline Lp-PLA 2 activity level.
The univariable relationships between Lp-PLA 2 activity and background variables were evaluated using the chi-square and Kruskal-Wallis tests for categorical and continuous variables, respectively. Multivariable analyses were used to evaluate the independent associations between baseline Lp-PLA 2 activity and other variables, using linear regression models in which continuous variables were included as linear or log-transformed variables, as appropriate. Baseline Lp-PLA 2 activity as a predictor of outcomes was evaluated using Kaplan-Meier estimates of the cumulative risk to the first occurrence of an event for the Lp-PLA 2 quartile groups. The independent associations between baseline Lp-PLA 2 activity levels and outcomes were evaluated using adjusted Cox regression models in which the HR and 95% CI were calculated using the lowest quartile group of Lp-PLA 2 activity (quartile 1) as the reference and performing a trend analysis across quartile groups. The predefined adjustment variables for the statistical analyses were randomized treatment, geographic region, age, sex, body mass index, current smoking, hypertension, diabetes mellitus, prior MI, prior coronary revascularization, multivessel CHD, polyvascular disease, significant renal dysfunction, levels of standard biomarkers (hemoglobin, white blood cell count, estimated glomerular filtration rate [Chronic Kidney Disease Epidemiology Collaboration], low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and triglycerides), and levels of prognostic biomarkers (high-sensitivity cardiac troponin T, N-terminal proB-type natriuretic peptide, growth differentiation factor 15, high-sensitivity C-reactive protein, interleukin 6), which were entered as quartiles after log transformation. A Cox proportional hazards model with treatment group (darapladib or placebo), baseline Lp-PLA 2 activity categorized by quartile group, and treatment group Lp-PLA 2 activity interaction as independent variables was used to test whether the treatment effect differed in relation to Lp-PLA 2 activity level. The relevance of the Lp-PLA 2 activity interacting with the effect of treatment was evaluated based on the significance of interaction statistics. Data were handled by complete-case analyses with no imputation for missing values. No correction for multiplicity was performed. The analyses of associations between the Lp-PLA 2 activity and baseline characteristics, other biomarkers and outcomes, and changes of Lp-PLA 2 activity over time were prespecified in the statistical analysis plans.
Lp-PLA 2 activity over time
The HRs and P values for the association of changes in Lp-PLA 2 activity after 1 month and clinical outcomes were estimated using a Cox proportional hazards regression model with baseline Lp-PLA 2 activity and change from baseline to month 1 in Lp-PLA 2 activity as the covariate, stratified by treatment. In the 100-participant cohort, Lp-PLA 2 activity over time was characterized using the generalized estimating equations model with participants fitted as a repeated effect, and it included the following terms: treatment, visit, baseline Lp-PLA 2 activity, treatment by visit, and baseline by visit The full model contained the following data: randomized treatment, geographic region, age, sex, body mass index, current smoking, hypertension, diabetes mellitus, prior myocardial infarction, prior coronary revascularization, multivessel coronary heart disease, polyvascular disease, significant renal dysfunction, routine biochemical variables (hemoglobin, white blood cell count, estimated glomerular filtration rate [Chronic Kidney Disease Epidemiology Collaboration], low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and triglycerides), and prognostic biomarkers (N-terminal proB-type natriuretic peptide, high-sensitivity cardiac troponin T, cystatin C, high-sensitivity C-reactive protein, and interleukin 6). Lp-PLA 2 indicates lipoprotein-associated phospholipase A 2 ; MACE, major adverse cardiac events; MCE, major coronary events; MI, myocardial infarction; NRI, net reclassification index.
interactions. Point estimates, 95% CIs, and P values for the mean differences between patients treated with darapladib and placebo at months 1, 3, 6, and 18, and at the end of treatment were calculated using this generalized estimating equations model.
Results
For the 14 500 patients with Lp-PLA 2 activity measurements, baseline characteristics were representative of the overall STABILITY population and balanced between the randomized treatment groups (Table 1 ). There were no differences in rates of outcome events between patients with and without Lp-PLA 2 activity measurements. The distribution of the Lp-PLA 2 activity levels did not deviate from normality (median 172 lmol/min per liter [interquartile range 143-204 lmol/min per liter]). There were statistically significant differences for the majority of the baseline characteristics and levels of other biomarkers when stratifying patients by baseline Lp-PLA 2 quartile groups ( Table 1 ). The following factors showed independent and relevant associations with higher Lp-PLA 2 activity in multivariable analyses: male sex, North American origin, current smoking, higher low-density lipoprotein cholesterol level, and lower high-density lipoprotein cholesterol level. Diabetes mellitus was associated with lower Lp-PLA 2 activity (Table 2 ).
In the present cohort, 661 (4.6%) cardiovascular deaths, 695 (4.8%) MIs, and 280 (1.9%) strokes occurred. Of the 661 cardiovascular deaths, 142 deaths of unknown cause were not verified as noncardiovascular and thus were included among the cardiovascular deaths. In total, there were 1444 (10.0%) first primary outcome events and 1404 (9.7%) major coronary events. The outcome events were accrued at a stable rate during follow-up (Figure 1 ). There was a significant difference in event rates between the highest quartile group of baseline Lp-PLA 2 activity in comparison to the lower 3 quartile groups, among which no significant differences in event rates were observed (Figures 1 and 2) . The higher event rates in the highest Lp-PLA 2 quartile group were observed for all types of events, namely, the primary composite of cardiovascular death, MI, or stroke; the secondary composite of major coronary events; and the individual events cardiovascular death, MI, stroke, hospitalization for heart failure, and cardiovascular and total mortality. The elevated event rates of all of these events in the highest Lp-PLA 2 quartile group were maintained after adjusting for baseline characteristics and conventional laboratory tests. In addition, after adjustment for the prognostic biomarkers N-terminal proB-type natriuretic peptide, highsensitivity cardiac troponin T, growth differentiation factor 15, cystatin C, high-sensitivity C-reactive protein, and interleukin 6, the increased risks of the composite events, hospitalization for heart failure, cardiovascular death, and total death remained, Figure 2A ). These findings were similar in men and women, without any interaction with sex ( Figure 2B and 2C ). The addition of Lp-PLA 2 activity levels to the model including all clinical characteristics, risk factors, and other biomarkers provided no significant change of the c-index and only a modest improvement of the net reclassification index for most events based on better discrimination of patients without increased risk (Table 3) . At 1 month, the Lp-PLA 2 activity was reduced from a median of 172 to 57 lmol/min per liter (interquartile range 42-75 lmol/min per liter, mean reduction 112 lmol/min per liter, mean percentage reduction 64%) in the darapladib group compared with a median decrease from 173 to 164 lmol/min per liter (interquartile range 136-196 lmol/ min per liter, mean reduction 9 lmol/min per liter, mean percentage reduction 4%) in the placebo group. Darapladib treatment produced a persistent %65% relative reduction in Lp-PLA 2 activity from the first on-treatment measurement at 1 month until study termination, whereas the placebo group had no significant change in Lp-PLA 2 activity (Figure 3) . The changes in Lp-PLA 2 activity were consistent in all subgroups based on clinical characteristics or biomarkers (Table 4) .
In the highest Lp-PLA 2 quartile group, there was no significant reduction in the primary composite end point of cardiovascular death, MI, or stroke (HR 0.86, 95% CI 0.72-1.03), whereas the secondary composite end point of major coronary events showed a statistically significant reduction (HR 0.82, 95% CI 0.68-0.98); however, there were no significant interactions between quartile groups of baseline Lp-PLA 2 activity and the effects of darapladib (Figures 4 and  5) . Finally, there were no significant associations between either the level of Lp-PLA 2 activity at 1 month or the reduction in Lp-PLA 2 activity and any of the outcome events in the trial (Tables 5 through 8) .
Discussion
This prespecified analysis of the STABILITY trial in patients with stable CHD followed for 3.7 years on a background of optimal medical therapy verified that Lp-PLA 2 activity is a marker of overall cardiovascular risk and total mortality in patients with stable CHD, in accordance with previous studies. [6] [7] [8] [9] Dyslipidemia, male sex, current smoking, and living in the North American region were associated with higher Lp-PLA 2 activity, in agreement with other observations. 21 After adjusting for both baseline characteristics and other prognostic biomarkers, Lp-PLA 2 activity remained a significant marker of composite cardiovascular events, hospitalization for heart failure, and cardiovascular and total mortality, whereas the associations with new ischemic events such as MI and stroke were attenuated. The finding of an independent association between Lp-PLA 2 activity and composite cardiovascular events is in accordance with most 6-9,22-27 although not all 28 previous studies of stable patients at high risk for or with established CHD. The rather weak independent association with a raised risk of cardiovascular events when adjusting for other biomarkers might be a corollary to the lack of association between Lp-PLA 2 activity and outcomes in patients with acute coronary syndromes having pronounced elevations of other prognostic biomarkers. 29 Darapladib treatment persistently reduced Lp-PLA 2 activity by %65% in all patient groups, consistent with other findings. 16, 18, 29 Reduction in Lp-PLA 2 activity was not associated with any significant effect on the primary composite outcome of cardiovascular death, MI, or stroke in the STABILITY trial overall or with any subgroup based on the Lp-PLA 2 activity level at baseline. This lack of effect in the overall trial and in all Lp-PLA 2 activity subgroups is in agreement with the findings from the SOLID trial of patients with recent acute coronary syndromes. 29 In addition, in the present study, there were no significant associations between any outcome and the magnitude of reduction in Lp-PLA 2 activity level by darapladib treatment. These accumulated experiences show that although high Lp-PLA 2 activity was associated with an increased risk of cardiovascular events, pharmacological lowering of Lp-PLA 2 activity was not a useful treatment target for prevention of cardiovascular events in patients with stable CHD. Prior to the current study, several lines of evidence supported Lp-PLA 2 activity as a risk indicator of adverse outcomes both in patients with stable CHD and in the general population in addition to being potentially involved in the development of atherosclerosis and vulnerable plaque at the tissue level. [6] [7] [8] [9] [22] [23] [24] [25] [26] [27] Furthermore, in 2 case-control studies, natural deficiency of Lp-PLA 2 activity due to carriage of the V279F-null allele in the Lp-PLA 2 gene was associated with a lower risk of developing CHD. 30 In a recent study in European CHD patients, a single-nucleotide polymorphism of the Lp-PLA 2 gene was found to be associated with both increased Lp-PLA 2 activity in plasma and a raised risk of MI. 31 Lp-PLA 2 has also been shown to be highly concentrated in unstable and ruptured atherosclerotic plaques and to be strongly expressed in macrophages in lesions prone to rupture. 16 Direct inhibition of Lp-PLA 2 activity prevented progression to advanced coronary atherosclerotic lesions in diabetic and hypercholesterolemic swine. 17 Finally, in a phase II trial, darapladib appeared to stabilize the necrotic core size and plaque burden in coronary atherosclerotic plaques compared with placebo 18 ;
therefore, it was a logical hypothesis that inhibition of Lp-PLA 2 activity with darapladib might lead to clinical benefit, especially in patients with high Lp-PLA 2 activity at baseline and/or a pronounced reduction by the treatment. 27 Nevertheless, this current study, based on 3 to 5 years darapladib treatment and Lp-PLA 2 activity levels that were available for %14 500 patients before and during treatment and with a consistent %65% reduction of the Lp-PLA 2 activity in all patient groups, showed no associated effects of darapladib on clinical outcomes. This finding clearly refutes any clinically important effects of darapladib for prevention of cardiovascular events in patients with CHD. The current findings corroborate other studies showing that patients with stable CHD and high Lp-PLA 2 activity have a raised risk of cardiovascular events and total mortality. The increase in risk with Lp-PLA 2 activity was not linear but was most pronounced in the %25% of patients with the highest levels. The increased risk associated with high Lp-PLA 2 activity was independent of demographics, clinical characteristics, and conventional biochemical risk indicators such as dyslipidemia, dysglycemia, anemia, and renal dysfunction. When adjusting for cardiac, inflammatory, and renal function biomarkers, the independent associations between Lp-PLA 2 activity and cardiovascular and total mortality and Figure 4 . Effect of darapladib compared with placebo in relation to baseline Lp-PLA 2 activity (lmol/min per liter) quartile groups concerning all outcomes. MACE specifies CV death, MI, or stroke; MCE specifies coronary heart disease death, MI, or urgent coronary revascularization. Event rates are Kaplan-Meier rates. CV indicates cardiovascular; HR, hazard ratio; Lp-PLA 2 , lipoprotein-associated phospholipase A 2 ; MACE, major adverse cardiac events; MCE, major coronary events; MI, myocardial infarction.
hospitalization for heart failure remained, whereas the associations with ischemic events were attenuated. Similarly, there was no association between Lp-PLA 2 activity and cardiovascular outcomes in patients with acute coronary syndromes, in which the majority have elevated cardiac and inflammatory markers. 29 Without an associated indication for a specific treatment, it is unlikely that Lp-PLA 2 activity will be used for identification of patients at high risk, considering the competition with other already generally available and more specific prognostic biomarkers. In the present study, as in a previous study, 32 there was an inverse relationship between Lp-PLA 2 activity and diabetes mellitus. In that study, diabetes mellitus was associated with a redistribution of Lp-PLA 2 activity from low-to high-density lipoprotein particles. 32 These complex interactions among Lp-PLA 2 activity, glucose, and lipoprotein metabolism might need to be considered in future studies of the importance of Lp-PLA 2 activity for cardiovascular events in different patient populations.
Conclusions
Based on the experiences from 3 to 5 years of darapladib treatment and available Lp-PLA 2 activity levels before and during treatment in 14 500 patients with stable CHD, high pretreatment Lp-PLA 2 activity was associated with an increased risk of cardiovascular events; however, pharmacological lowering of Lp-PLA 2 activity did not significantly reduce cardiovascular events, regardless of the baseline level or degree of reduction of Lp-PLA 2 activity. 
